Clinical guidance as outlined in product labeling and patient information for hormone therapy recommends use at the lowest effective dose for the shortest duration of time.
Wyeth continues to support the appropriate use of hormone therapy and encourages women experiencing menopausal symptoms to speak with a health care professional to determine whether it might be the right treatment option for them.
Hormone therapy is not right for all women, and it does not prevent heart disease or dementia. Hormone therapy may increase a woman's chance of heart attack, stroke, breast cancer or blood clots and should be taken at the lowest effective dose for the shortest time based on her goals and risks. If a woman has a uterus, estrogens increase the risk of uterine cancer. Adding a progestin greatly reduces this risk. Women should re-evaluate the use of estrogens and progestins with their health care professional. If a woman is not having symptoms, non-estrogen treatments should be considered before starting therapy to prevent bone loss.
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts a
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved